Key statistics
On Friday, Atossa Therapeutics Inc (ATOS:NAQ) closed at 4.20, 11.70% above the 52 week low of 3.76 set on Feb 12, 2026.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 3.92 |
|---|---|
| High | 4.44 |
| Low | 3.91 |
| Bid | 4.00 |
| Offer | 4.19 |
| Previous close | 3.94 |
| Average volume | 315.04k |
|---|---|
| Shares outstanding | 8.61m |
| Free float | 8.58m |
| P/E (TTM) | -- |
| Market cap | 36.17m USD |
| EPS (TTM) | -3.52 USD |
Data delayed at least 15 minutes, as of Feb 13 2026 21:00 GMT.
More ▼
Press releases
- Atossa Therapeutics Issues Letter to Shareholders Highlighting 2025 Accomplishments and 2026 Outlook
- Atossa Therapeutics Maintains Strong Market Position for (Z)-Endoxifen for Duchenne Muscular Dystrophy as Congress Reauthorizes Priority Review Voucher Program
- Atossa Therapeutics' Founder and CEO Steven Quay, M.D., Ph.D. Named One of The Top 50 Healthcare Technology CEOs of 2025
- Atossa Therapeutics Receives FDA Orphan Drug Designation for (Z)-Endoxifen for the Treatment of Duchenne Muscular Dystrophy
- Atossa Therapeutics Receives FDA "Study May Proceed" Letter for (Z)-Endoxifen Investigational New Drug Application for Metastatic Breast Cancer
- Atossa Therapeutics Wins 2025 Clinical Trials Arena Research and Development Excellence Award in Precision Endocrine Therapy Category
- Atossa Therapeutics Presents Four Clinical Trial Updates Highlighting (Z)-Endoxifen Research at the 2025 San Antonio Breast Cancer Symposium
- Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen for Duchenne Muscular Dystrophy
- Atossa Therapeutics Announces Issuance of U.S. Patent Covering Enteric Oral (Z)-Endoxifen Formulations and Methods of Treating Patients Using (Z)-Endoxifen
- Atossa Therapeutics Details Accelerated FDA Strategy to Advance (Z)-Endoxifen Across Breast Cancer Continuum
More ▼
